ATE403436T1 - Polykationische karbohydrate als immunostimulierende mittel in impstoffen - Google Patents

Polykationische karbohydrate als immunostimulierende mittel in impstoffen

Info

Publication number
ATE403436T1
ATE403436T1 AT00912788T AT00912788T ATE403436T1 AT E403436 T1 ATE403436 T1 AT E403436T1 AT 00912788 T AT00912788 T AT 00912788T AT 00912788 T AT00912788 T AT 00912788T AT E403436 T1 ATE403436 T1 AT E403436T1
Authority
AT
Austria
Prior art keywords
vaccines
polycationic
carbohydrates
polycationic carbohydrates
immunostimulant agents
Prior art date
Application number
AT00912788T
Other languages
English (en)
Inventor
Hazire Oya Alpar
James Edward Eyles
Satyanarayana Somavarapu
Ethel Diane Williamson
Leslie William James Baillie
Original Assignee
Secr Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906696.1A external-priority patent/GB9906696D0/en
Priority claimed from GBGB9906694.6A external-priority patent/GB9906694D0/en
Application filed by Secr Defence filed Critical Secr Defence
Application granted granted Critical
Publication of ATE403436T1 publication Critical patent/ATE403436T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00912788T 1999-03-24 2000-03-23 Polykationische karbohydrate als immunostimulierende mittel in impstoffen ATE403436T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9906696.1A GB9906696D0 (en) 1999-03-24 1999-03-24 Vaccine composition
GBGB9906694.6A GB9906694D0 (en) 1999-03-24 1999-03-24 Vaccine composition

Publications (1)

Publication Number Publication Date
ATE403436T1 true ATE403436T1 (de) 2008-08-15

Family

ID=26315329

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00912788T ATE403436T1 (de) 1999-03-24 2000-03-23 Polykationische karbohydrate als immunostimulierende mittel in impstoffen

Country Status (11)

Country Link
US (1) US20080057083A1 (de)
EP (2) EP1163001A2 (de)
JP (3) JP2002540076A (de)
AT (1) ATE403436T1 (de)
AU (2) AU762078B2 (de)
CA (2) CA2366908A1 (de)
DE (1) DE60039754D1 (de)
DK (1) DK1163002T3 (de)
ES (1) ES2311451T3 (de)
NZ (1) NZ514323A (de)
WO (2) WO2000056362A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050181063A1 (en) * 2000-03-22 2005-08-18 Alpar Hazire O. Pharmaceutical composition for administration to mucosal surfaces
AU2001276831A1 (en) 2000-06-22 2002-01-02 Rxkinetix, Inc. Delivery vehicle composition and methods for delivering antigens and other drugs
WO2002000171A2 (en) 2000-06-26 2002-01-03 Rxkinetix, Inc. Composition for delivery of hematopoietic growth factor
EP1417236A4 (de) * 2001-07-10 2010-03-17 Corixa Corp Zusammensetzungen und verfahren zur abgabe von proteinen und adjuvantien in einer mikrokügelchen-kapsel
ES2295391T3 (es) 2001-08-16 2008-04-16 Cmp Therapeutics Limited Microparticulas de quitina y sus usos medicos.
EP1432402B1 (de) * 2001-10-03 2006-11-22 Celator Pharmaceuticals, Inc. Zusammensetzungen zur verabreichung von arzneimittelkombinationen
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0300885D0 (en) * 2003-01-15 2003-02-12 Secr Defence Pharmaceutical composition
JP4675317B2 (ja) * 2003-01-30 2011-04-20 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アジュバント化インフルエンザワクチン
JP2006516609A (ja) * 2003-01-30 2006-07-06 カイロン ソチエタ ア レスポンサビリタ リミタータ 粘膜髄膜炎菌性ワクチン
CA2528007C (en) 2003-06-02 2012-03-27 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
JP4669665B2 (ja) * 2004-04-12 2011-04-13 正彦 阿部 細胞毒性のないポリカチオン修飾リポソームおよびその製造方法
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
EP1991204A2 (de) 2006-02-24 2008-11-19 Novartis AG Mikropartikel mit biologisch abbaubarem polymer und kationischem polysaccharid zur verwendung für immunogene zusammensetzungen
WO2008041703A1 (en) * 2006-10-02 2008-04-10 Osaka University Adjuvant for influenza vaccine and influenza vaccine
JP5297009B2 (ja) * 2007-07-24 2013-09-25 大日精化工業株式会社 免疫アジュバント水溶液
MY148321A (en) * 2007-10-02 2013-03-29 Malaysian Palm Oil Board Mpob Vitamin e supplementation to tetanus toxoid
GB0721937D0 (en) 2007-11-08 2007-12-19 Secr Defence Rodenticide
EP2328614A1 (de) * 2008-08-06 2011-06-08 Novartis AG Mikroteilchen zur verwendung in immunogenen zusammensetzungen
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
ES2728653T3 (es) * 2011-05-18 2019-10-28 Matrivax Inc Composiciones vacunales con una matriz proteica que incluye policationes
US10500283B2 (en) 2011-05-30 2019-12-10 National Institute Of Immunology Vaccine composition capable of inducing memory antibody response from single point immunization
CN107200788B (zh) * 2017-05-11 2020-04-14 暨南大学 一种季鏻化壳聚糖及其作为疫苗免疫佐剂的应用
CN107899021A (zh) * 2017-11-06 2018-04-13 扬州大学 一种表面修饰s‑层蛋白的壳聚糖微球、制备及应用
KR102384808B1 (ko) * 2018-12-20 2022-04-08 주식회사 스킨메드 키토산으로 코팅된 나노 캡슐 및 이의 용도
EP3960203A1 (de) 2020-08-25 2022-03-02 Université de Liège Komplexe zur abgabe von proteinischen wirkstoffen

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) * 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
GB1290141A (de) * 1968-05-31 1972-09-20
FR2306684A1 (fr) * 1975-04-11 1976-11-05 Crinex Lab Nouvelle composition a action immunostimulante
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
EP0283085B1 (de) * 1987-03-17 1992-11-11 Akzo N.V. Adjuvanzienmischung
EP0382271B1 (de) * 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocole als Impfstoffadjuvans
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
DE4004430A1 (de) * 1990-02-09 1991-08-14 Schering Ag Aus polyaldehyden aufgebaute kontrastmittel
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5292513A (en) * 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
JPH08508247A (ja) * 1993-03-11 1996-09-03 セクレテック，インク． 粘膜表面への免疫原の輸送における重合的粘膜付着体
US6913767B1 (en) * 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
CA2207961A1 (en) * 1995-01-05 1996-07-11 Robert J. Levy Surface-modified nanoparticles and method of making and using same
ES2185762T3 (es) * 1995-03-13 2003-05-01 Secr Defence Vacunas contra la peste.
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
DE19603649A1 (de) * 1996-02-01 1997-08-07 Werner Lubitz Rekombinante Expression von S-Layer-Proteinen
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
GB9810126D0 (de) * 1998-05-13 1998-07-08 Glaxo Group Ltd
DK1126826T6 (en) * 1998-11-02 2019-06-24 Alkermes Pharma Ireland Ltd Multiparticulate modified release of methylphenidate
US20030171258A1 (en) * 1999-03-24 2003-09-11 Alpar Hazire Oya Particle based vaccine composition
US20020103165A1 (en) * 2000-02-29 2002-08-01 Alliance Pharmaceutical Corp., Engineered spray-dried lipid-based microparticles for cellular targeting
US20050181063A1 (en) * 2000-03-22 2005-08-18 Alpar Hazire O. Pharmaceutical composition for administration to mucosal surfaces
GB0300885D0 (en) * 2003-01-15 2003-02-12 Secr Defence Pharmaceutical composition

Also Published As

Publication number Publication date
WO2000056362A2 (en) 2000-09-28
CA2366216A1 (en) 2000-09-28
WO2000056362A3 (en) 2001-02-01
JP2002540077A (ja) 2002-11-26
ES2311451T3 (es) 2009-02-16
AU3442400A (en) 2000-10-09
JP2002540076A (ja) 2002-11-26
WO2000056361A2 (en) 2000-09-28
CA2366908A1 (en) 2000-09-28
CA2366216C (en) 2012-10-23
JP2012031186A (ja) 2012-02-16
EP1163001A2 (de) 2001-12-19
NZ514323A (en) 2003-03-28
AU755502C (en) 2003-08-14
AU762078B2 (en) 2003-06-19
DE60039754D1 (de) 2008-09-18
AU3443500A (en) 2000-10-09
JP5124066B2 (ja) 2013-01-23
EP1163002B1 (de) 2008-08-06
DK1163002T3 (da) 2009-01-19
EP1163002A2 (de) 2001-12-19
AU755502B2 (en) 2002-12-12
US20080057083A1 (en) 2008-03-06
WO2000056361A3 (en) 2001-03-01

Similar Documents

Publication Publication Date Title
ATE403436T1 (de) Polykationische karbohydrate als immunostimulierende mittel in impstoffen
IL145982A0 (en) Vaccines
NO954996D0 (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
GB0118238D0 (en) Medicaments
GB0112836D0 (en) Medicaments
WO2005011655A3 (en) Pyridazine derivatives and their use as therapeutic agents
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
WO2003096989A3 (en) Anti tubercular drug: compositions and methods
GB9917406D0 (en) Compounds
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
MXPA02005563A (es) Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma.
MY136386A (en) New combination of a betablocker and a cholesterol-lowering agent
MXPA04001912A (es) Aminobenzofenonas novedosas.
MY127452A (en) Vaccines.
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
EP1303300A4 (de) Zusammensetzungen und methoden zur behandlung von candidosen
CA2394843A1 (en) A vaccine comprising lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
MY110074A (en) Pharmacuetical formulation.
WO2002057281A3 (en) Aminoglycosides as antibiotics
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
WO2000057919A3 (en) Lipid-based artificial particles inducing cell-mediated immunity
AU2003285125A1 (en) Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
Tabatadze New Host Insects of Aschersonia Species

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1163002

Country of ref document: EP